LIGAND PHARMACEUTICALS INCORPORATED Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (31)

Latest Posts

About This Stock More About This Stock
Most Shorted Major Stocks Of February 2019
Article By: TheTechnicals
Sunday, February 17, 2019 10:39 PM EDT
It may seem the current rally in stocks will keep going until we break all-time highs and beyond. Others are not nearly so bullish. Traders and investors who have a bearish bias will look to short stocks. Here is our list of the most shorted stocks.
In this article: LGND, MTCH, RH, CVNA, AKCA, TSLA
Read
Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal
Article By: ChinaBio® Today
Saturday, June 30, 2018 4:25 PM EDT
CStone Pharma of Suzhou acquired rights to a novel cancer drug from Agios in a deal worth up to $424 million. CStone will have rights to ivosidenib in greater China. It will initially target acute myeloid leukemia (AML) and cholangiocarcinoma.
In this article: AGIO, LGND, NVS, ZLAB
Read
3 Biotech Stocks Up In The Past Month On Industry Turnaround
Article By: Zacks Investment Research
Tuesday, June 5, 2018 1:08 PM EDT
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front.
In this article: BMRN, LGND, VVUS Also: JNJ
Read
Spectrum (SPPI) Earnings And Sales Beat Estimates In Q1
Article By: Zacks Investment Research
Saturday, May 5, 2018 9:05 PM EDT
Spectrum Pharma’s shares have underperformed the industry so far this year. The stock has lost 16.5% against the industry’s decline of 5%. Plus more news on Amgen, Ligand Pharmaceuticals and Protagonist Therapeutics.
In this article: SPPI, AMGN, LGND, PTGX
Read
4 Top-Ranked Drug/Biotech Stocks To Buy As Q1 Nears End
Article By: Zacks Investment Research
Tuesday, March 27, 2018 8:42 AM EDT
After a solid run in the first two months of the first quarter, the drug/biotech sectors struggled in March, probably on broader market pressure and a few negative updates on the pipeline and regulatory front.
In this article: GSK, LGND, HLUYY, ADVM Also: PFE, SNY, CELG
Read

PARTNER HEADLINES

Latest Tweets for $LGND

No tweets yet!